Product Description
Mechanisms of Action: Glycosaminoglycan Degrader
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: Seikagaku
Company Location: Asia Pacific
Company Founding Year: 1947
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Other|Intervertebral Disc Displacement|Spinal Diseases|Intervertebral Disc Degeneration
Phase 2: Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01282606 |
NCT01282606 | P2 |
Completed |
Other |
2012-08-01 |
2019-03-19 |
Treatments |
|
NCT03607838 |
Discovery 6603 Study | P3 |
Completed |
Intervertebral Disc Displacement |
2022-08-03 |
22% |
2025-07-12 |
Primary Endpoints|Start Date|Treatments |
NCT02421601 |
NCT02421601 | P3 |
Completed |
Spinal Diseases|Intervertebral Disc Degeneration|Intervertebral Disc Displacement |
2018-02-01 |
2019-03-20 |
Treatments |
|
2014-001449-26 |
2014-001449-26 | P3 |
Completed |
Unknown |
2017-03-17 |
2025-06-06 |
Treatments |
|
NCT01941563 |
NCT01941563 | P3 |
Completed |
Intervertebral Disc Degeneration|Intervertebral Disc Displacement|Spinal Diseases |
2015-11-01 |
2019-03-20 |
Treatments |
|
NCT00634946 |
Phase II/III Study | P3 |
Completed |
Other |
2009-11-01 |
2019-03-18 |
Treatments |